Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cibus Europe B V is currently focused on the Biotechnology & Pharmaceuticals technology area. The portfolio shows 1 pending office action, which represents the current scope of the company's active prosecution. This 1 pending office action indicates a targeted approach to securing intellectual property rights in the Biotechnology & Pharmaceuticals sector.
The prosecution is concentrated within 1 distinct art unit and involves 1 distinct examiner. This level of concentration suggests that the company's current applications are being evaluated within a specific technical and administrative framework. For a practitioner, the involvement of 1 distinct examiner means that the prosecution strategy is not spread across different perspectives at the patent office.
BOGGS, RUSSELL T is the busiest examiner for the portfolio, with a busiest examiner pending count of 1. This examiner is responsible for the 1 pending office action currently active. The success of the company's pending matters is closely tied to the examination style of BOGGS, RUSSELL T, who is the 1 examiner identified. Practitioners should monitor the actions of BOGGS, RUSSELL T to anticipate the next steps for this portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEVEAU ROSEN, JASON | 1 | 80.1% | +16.5% |
| BOGGS, RUSSELL T | 1 | 73.2% | +15.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18752480 | SHATTERPROOF GENES AND MUTATIONS | DEVEAU ROSEN, JASON | 1d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18752480 | SHATTERPROOF GENES AND MUTATIONS | DEVEAU ROSEN, JASON | 1d overdue |
| 18092420 | METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR | BOGGS, RUSSELL T | 28d |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18752480 | SHATTERPROOF GENES AND MUTATIONS | DEVEAU ROSEN, JASON | 1662 | §103§112Other | Final Rejection | 1d overdue | Pending | Jun 24, 2024 |
| 18092420 | METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR | BOGGS, RUSSELL T | 1663 | §103Other | Final Rejection | 28d | Pending | Jan 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial